Clinuvel Pharmaceuticals Limited (CLVLF)

OTHER OTC:CLVLF

CLVLF

Clinuvel Pharmaceuticals

RESEARCH TOOLSreports

Clinuvel Pharmaceuticals (CLVLF) Price & Analysis

43 Followers

CLVLF Stock Chart & Stats

$7.23

-$0.52(-6.64%)

At close: Jan 08 4:00 PM EST

$7.23

-$0.52(-6.64%)

Day’s Range― - ―

52-Week Range$5.79 - $8.93

Previous CloseN/A

Volume151.00

Average Volume (3M)121.00

Market Cap

$313.88M

Enterprise Value$424.45M

Total Cash (Recent Filing)$233.00M

Total Debt (Recent Filing)$341.09K

Price to Earnings (P/E)13.6

Beta0.26

Next Earnings

Sep 01, 2026

EPS Estimate

0.37

Next Dividend Ex-DateN/A

Dividend Yield0.42%

Share Statistics

EPS (TTM)0.65

Shares Outstanding50,427,900

10 Day Avg. Volume205

30 Day Avg. Volume121

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.16

Price to Sales (P/S)5.47

P/FCF Ratio12.74

Enterprise Value/Market Cap1.35

Enterprise Value/Revenue4.41

Enterprise Value/Gross Profit6.92

Enterprise Value/Ebitda10.19

Forecast

1Y Price Target

$19.83

Price Target Upside174.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.52

Revenue Forecast (FY)$69.03M

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetA large cash position and two decades operating without debt give durable financial flexibility. Low leverage reduces refinancing and solvency risk, enabling self-funding of clinical programs, manufacturing scale-up and commercial expansion without reliance on dilutive or costly external financing.

Sustained ProfitabilityConsistent profitability across multiple periods demonstrates resilient unit economics and disciplined commercial execution. Profitability supports reinvestment into R&D and operations, lowers financing needs and signals that the core business model can generate free cash across business cycles.

Improving Market Access And ScaleRegulatory and commercial progress—expanded dosing allowance and broadening site coverage—structurally increase addressable usage and distribution capacity. These changes underpin sustainable volume growth and higher utilization of SCENESSE across approved markets over the medium term.

Bears Say

Rising Operating ExpensesMaterial expense growth—personnel, commercial distribution and R&D consumables—raises structural operating leverage. If revenue growth remains modest, sustained expense escalation can compress margins, increase cash burn volatility and reduce the pace at which investments translate into profitable scale.

Regulatory & Timing RiskSequential trial completion requirements and pending SEC/ADR feedback create durable timing uncertainty for key filings and market expansions. Delays in approvals or listings will postpone potential new‑indication revenues and heighten execution risk for the company's diversification strategy.

Single‑product ConcentrationRevenue dependence on one product concentrates commercial and reimbursement risk. Long‑term growth and resilience hinge on SCENESSE uptake, payer decisions and site access; any competitive, reimbursement or supply disruption could materially affect company cash flows and strategic flexibility.

Clinuvel Pharmaceuticals News

Clinuvel Issues 887,956 Unquoted Performance Rights Under Incentive Scheme

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals has notified the market of the issue...

1M ago

Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals is a Melbourne‑based specialty drug developer focused...

1M ago

FDA Drops QT Study Requirement for Clinuvel’s SCENESSE

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals said the U.S. Food and...

2M ago

Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals has received final scientific advice from the...

2M ago

Clinuvel Performance Rights Lapse After Conditions Not Met

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an announcement. Clinuvel Pharmaceuticals has announced the cessation of 46,067 performance...

2M ago

Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals has issued 227,158 fully paid...

2M ago

Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel used the 2026 American Academy of Dermatology Annual...

2M ago

Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals is showcasing its melanocortin-based programs...

3M ago

Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals reported its strongest first-half financial performance, maintaining...

3M ago

Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues...

4M ago

CLVLF FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest stock price was $5.79 and its highest was $8.93 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is $313.88M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 82 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported $0.145 earnings per share for the quarter, missing the consensus estimate of $0.207 by -$0.061.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited pays a Annually dividend of $0.033 which represents an annual dividend yield of 0.42%. See more information on Clinuvel Pharmaceuticals Limited dividends here

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.37.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,427,900 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of $0.145 in its last earnings report, missing expectations of $0.207. Following the earnings report the stock price went down -6.143%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in CLVLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

13.29%

Trailing 12-Months

Asset Growth

22.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Clinuvel Pharmaceuticals (CLVLF) Earnings & Revenues

Historic Earnings Reports

CLVLF Company Deck

CLVLF Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all CLVLF earnings summaries

CLVLF Stock 12 Month Forecast

Average Price Target

$19.83

▲(174.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","28":"$28","10.75":"$10.75","16.5":"$16.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27.6685752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.8338511,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.999127,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.75,16.5,22.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.605,8.225275015384616,9.845550030769232,11.465825046153846,13.086100061538462,14.706375076923077,16.32665009230769,17.94692510769231,19.567200123076923,21.187475138461537,22.807750153846154,24.428025169230768,26.048300184615382,{"y":27.6685752,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.605,7.622603930769231,8.640207861538462,9.657811792307694,10.675415723076924,11.693019653846154,12.710623584615385,13.728227515384617,14.745831446153847,15.763435376923077,16.78103930769231,17.79864323846154,18.81624716923077,{"y":19.8338511,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.605,7.019932846153846,7.434865692307692,7.849798538461538,8.264731384615384,8.67966423076923,9.094597076923076,9.509529923076922,9.924462769230768,10.339395615384614,10.75432846153846,11.169261307692306,11.584194153846154,{"y":11.999127,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.75,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.125,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.605,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.605,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >